Treatments for pyoderma gangrenosum: the STOP GAP RCT

Pyoderma gangrenosum is a rare inflammatory disorder that causes progressive necrotising ulceration. A retrospective cohort study of UK cases reported an age and sex adjusted incidence of 0.63 per 100,000 person years.
Currently there are no national or international guidelines covering the management of pyoderma gangrenosum. Patient information issued by the British Association of Dermatologists describes topical and systemic treatment options, as well as lesser used options such as intravenous steroids or biologics.
The most commonly prescribed topical treatments for pyoderma gangrenosum are potent steroid preparations and calcineurin inhibitors, and commonly prescribed systemic treatments include steroids and immunosuppressants.
In the STOP GAP study, the researchers set out to determine whether ciclosporin is superior to prednisolone for the treatment of pyoderma gangrenosum.
Read the full research:
www.bmj.com/content/350/bmj.h2958